- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02032771
Impact of M22 Synergistic Sequential Treatment (SST)
Impact of M22 Synergistic Sequential Treatment (SST) Using Intense Pulsed Light and Fractional Non-ablative Photothermolysis on Skin Texture
Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance.
Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation by at least 1 on the FES scale or ≥50% in category scale at 3 months follow-ups in at least 50% of the study population.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rhineland-Palatinate
-
Konz, Rhineland-Palatinate, Germany, 54329
-
-
-
-
Florida
-
Orlando, Florida, United States, 32801
- Knight Dermatology Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read, understand and provide written Informed Consent;
- Healthy adult, male or female, 30-65 years of age with Fitzpatrick-Goldman skin type I-V;
- Having suitable facial areas with wrinkles Fitzpatrick-Goldman Wrinkle and Elastosis Score of 3-6 to be treated;
- Having suitable facial areas with mild to moderate age/sun-related facial pigmentation
- Able and willing to comply with the treatment/follow-up schedule and requirements;
- Women of child-bearing age are required to be using a reliable method of birth control (such as an intrauterine device, birth control pills, condom with spermicidal, Nova ring, partner with vasectomy or abstinence) at least 3 months prior to enrollment and throughout the course of the study.
Exclusion Criteria:
- Skin type VI
- Pregnant, intending to become pregnant during the course of study, less than 3 months postpartum or less than 6 weeks after completion of breastfeeding
- Heavy smoker (>1 pack of cigarettes a day)
- Unable or unlikely to refrain from tanning, including the use of tanning booths, during the course of the study
- Use of photosensitive medication for which light exposure is contraindicated.
- Use of oral isotretinoin (Accutane®) within 3 months of initial treatment or during the course of the study. Note: skin must regain its normal degree of moisture prior to treatment.
- Having indurate acne in treated area.
- Any dermal/epidermal damage or disorder, mainly vascular or textural lesions, in treated area
- Prior treatment, such as chemical peel (especially phenol based) or dermabrasion, in treated area within 3 months of initial treatment or during the course of the study;
- Prior skin laser/light or another device treatment in treated area within 6 months of initial treatment or during the course of the study
- Prior use of collagen, fat injections or other methods of skin augmentation (enhancement with injected or implanted material) in treated area within 12 months of initial treatment or during the course of the study. Treatment may not be performed at all over permanent dermal implants
- Prior use of Botox in treatment area within 6 months
- Prior ablative resurfacing procedure or face lift in treated area with laser or other devices within 12 months of initial treatment or during the course of the study
- Any other surgery in treated area within 9 months of initial treatment or during the course of the study.
- Participation in a study of another investigational device or drug involving the same anatomical site within 3 months prior to enrollment or during this evaluation, or if not involving the same anatomical site, as per the Investigator's discretion
- History of keloid or any other type of hypertrophic scar formation or poor wound healing in a previously injured skin area
- Showing symptoms of hormonal disorders, as per the Investigator's discretion (such as Melasma, Chloasma)
- Concurrent inflammatory skin conditions, Open laceration or abrasion of any sort on area to be treated during the course of treatment
- Active Herpes Simplex at the time of treatment or having experienced more than three episodes of Herpes Simplex eruption within a year of study enrollment;
- Multiple dysplastic nevi in area to be treated
- Having a bleeding disorder or taking anticoagulation medications, including heavy use of aspirin, in a manner which does not allow for a minimum 10 day washout period prior to treatment (as per the subject's physician discretion)
- History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications
- Having any form of active cancer at the time of enrollment and during the course of the study or history of skin cancer on the face.
- Pigmented lesion in the treated area that appears cancerous or is not deemed suitable for photo therapy, as determined by a dermatologist.
- Significant concurrent illness, such as uncontrolled diabetes i.e. any disease state that in the opinion of the Investigator would interfere with the anesthesia, treatment, or healing process;
- Mentally incompetent, prisoner or evidence of active substance or alcohol abuse
- Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study.
- For subjects undergoing test spots: considerable undesired response consisting of skin hypopigmentation (long term whitening), a scar or pre scar formation, or any response deemed by the Investigator as grounds for exclusion.
- Allergies to anesthetics.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: M22 IPL and ResurFX
The procedure will include an intense pulse light (IPL) treatment followed by fractional non-ablative (FNA) treatment.
|
The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with ≥ 50% improvement in Fitzpatrick Elastosis Scale (FES)
Time Frame: 3 months following 3rd treatment
|
Skin improvement by Fitzpatrick Elastosis Scale (FES) or category scale at 3 months based on before/after photos
|
3 months following 3rd treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants with ≥ 50% improvement in Fitzpatrick Elastosis Scale (FES)
Time Frame: 1 and 6 months following 3rd treatment
|
Overall skin improvement at 1 and 6 months by subject and investigator evaluation compared to baseline using the category global aesthetic improvement (GAI) scale
|
1 and 6 months following 3rd treatment
|
Change in erythema/ edema/ purpura and the response intensity
Time Frame: Following treatments- Baseline, 4, 8 weeks
|
Immediate response (erythema, edema, purpura, etc.) of the skin will be assessed within 20-30 min post treatment by a 5 level scale: (0) None / (1) Trace / (2) Mild / (3) Moderate / (4) Severe.
|
Following treatments- Baseline, 4, 8 weeks
|
Downtime in days
Time Frame: Following treatment- baseline, 4, 8 weeks
|
Downtime defined as the period of time following the procedure during which the subject felt unable/unwilling to go out in public due to edema and / or erythema.
|
Following treatment- baseline, 4, 8 weeks
|
Subject Comfort using a Pain Visual Analogue Scale (VAS)
Time Frame: Following treatment- baseline, 4, 8 weeks
|
Subject assessment of pain and discomfort associated with treatments using a Pain Visual Analogue Scale (VAS), were 0 is "no pain" and 100 is "intolerable pain".
|
Following treatment- baseline, 4, 8 weeks
|
Subject subjective assessment of improvement using categorical improvement scales
Time Frame: Following treatments- 4, 8 weeks and 1, 3 and 6 months follow up
|
Subject subjective opinion of improvement and satisfaction with the treatment using the global aesthetic improvement (GAI) scale and pigment Improvement score.
|
Following treatments- 4, 8 weeks and 1, 3 and 6 months follow up
|
Number of Participants with Adverse Events
Time Frame: Following treatment #1, 2 and 3 and all follow up visits
|
Skin safety throughout the study as determined by the investigator by examining the post-treatment occurrences of complications and adverse events.
|
Following treatment #1, 2 and 3 and all follow up visits
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- LUM-ABU-M22-IPL&ResurFX-13-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Improvement of Wrinkles/Elastosis and/or Pigmentation
-
Lumenis Be Ltd.CompletedImprovement of Wrinkles/Elastosis as Well as General Skin ToneUnited States
-
LUTRONIC CorporationCompletedFace and Neck Wrinkles, Texture, PigmentationUnited States
-
Menarini (Thailand) LimitedCompletedSkin Roughness | Mottling | Blotchiness | Pigmentation | Fine WrinklesThailand
-
Alma Lasers Inc.Unknown
-
Federal University of Health Science of Porto AlegreCompletedEffect of a Program of Deep Inspiration Combined to Expiratory Positive Airway Pressure in AsthmaticImprovement of Functional Capacity. | Improvement of Quality of Life. | Improvement of Cardiovascular Autonomic Control.Brazil
-
South Valley UniversityIbn Sina Hospital; Qena Fertility Center, Qena, EgyptUnknownImprovement of Embryo Transfer Technique | Improvement of Implantation
-
Egyptian Atomic Energy AuthorityWaleed Nemr,Egyptian Atomic Energy AuthorityCompletedFacial Wrinkles - Rough Texture - HyperpigmentationEgypt
-
Cynosure, Inc.RecruitingScars | Wrinkles | Skin Laxity | Pigmentation | Stretch MarksUnited States
-
Federal University of Health Science of Porto AlegreInstituto de Cardiologia do Rio Grande do Sul; Coordenação de Aperfeiçoamento...UnknownImprovement of Functional Capacity. | Improvement of Quality of Life. | Improvement of Cardiovascular Autonomic Control. | Reduction of Blood Pressure in Hypertensive Patients.Brazil
-
Pusan National UniversityCompleted
Clinical Trials on M22 IPL and ResurFX
-
Lumenis Be Ltd.CompletedImprovement of Wrinkles/Elastosis as Well as General Skin ToneUnited States
-
Lumenis Be Ltd.Completed
-
Second Affiliated Hospital, School of Medicine,...RecruitingErythematotelangiectatic RosaceaChina
-
Lumenis Be Ltd.Completed
-
Goldman, Butterwick, Fitzpatrick and GroffNot yet recruitingKeratosis Pilaris
-
Acorda TherapeuticsPRA Health SciencesCompletedMultiple SclerosisUnited States
-
Alexandria UniversityRecruiting
-
Mayo ClinicCompletedDry Eye Syndrome | GVHD | Ocular RosaceaUnited States
-
Second Affiliated Hospital, School of Medicine,...Recruiting